{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:40:57Z","timestamp":1789342857536,"version":"build-2803163510"},"reference-count":47,"publisher":"BMJ","issue":"23","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Herein, we review interventional peripheral neuromodulatory approaches to reduce blood pressure (BP), specifically focusing on catheter-based renal denervation (RDN), as well as the latest data from recent clinical trials underpinning its clinical use. Given the apparent failure of established lifestyle measures and pharmacologic BP-lowering approaches to improve hypertension (HTN) control rates, the past decade has seen remarkable scientific efforts to explore the utility of interventional strategies for BP management. Experimental studies and human clinical trials have demonstrated the crucial role of the sympathetic nervous system in the development and mainenance of HTN - consequently, most recent interventional technologies aimed primarily at modulating neural pathways. Advanced approaches that were rigorously tested in human studies include RDN, endovascular baroreflex amplification, baroreflex activation therapy and cardiac neuromodulation stimulation.<\/jats:p>\n               <jats:p>Amongst these, RDN is by far the most established technology. With recent robust evidence from clinical trials and real-world data showing the safety and efficacy of both ultrasound and radiofrequency-based approaches, a recent clinical consensus statement of the European Society of Cardiology Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions concludes that RDN represents an ancillary therapeutic option in patients with uncontrolled resistant HTN confirmed by ambulatory blood pressure measurement and in spite of attention to lifestyle changes and optimised pharmacological treatment. Furthermore, RDN could alos be considered for patienst unlikley to adhere to or tolerate long-term antihypertensive drug treatment. Very recent data indicate long-term safety and efficacy up to 10 years. Appropriate implementation of RDN into clinical practice is now warranted.<\/jats:p>\n               <jats:p>For all other interventions additional data from adequately designed human studies are required to establish their safety and clinical utility for potential future use in routine practice.<\/jats:p>","DOI":"10.1136\/heartjnl-2022-321499","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T22:19:21Z","timestamp":1687558761000},"page":"1734-1740","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Update on advanced interventional neuromodulatory approaches to lower blood pressure"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"nct02439775","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03614260","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03503773","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02910414","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marcio Galindo","family":"Kiuchi","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, Medical School, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathy","family":"Carnagarin","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C","family":"Ward","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Santos","sequence":"additional","affiliation":[{"name":"Cardiology, Hospital Esperan\u00e7a Olinda, Olinda, Penambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia"},{"name":"Department of Nephrology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2025092004215557000_109.23.1734.1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.183"},{"key":"2025092004215557000_109.23.1734.2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835e2286"},{"key":"2025092004215557000_109.23.1734.3","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283652c61"},{"key":"2025092004215557000_109.23.1734.4","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-305063"},{"key":"2025092004215557000_109.23.1734.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.067"},{"key":"2025092004215557000_109.23.1734.6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01452"},{"key":"2025092004215557000_109.23.1734.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60566-3"},{"key":"2025092004215557000_109.23.1734.8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"The Lancet"},{"key":"2025092004215557000_109.23.1734.9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00392-015-0930-4","article-title":"Effects of catheter-based renal denervation on cardiac sympathetic activity and Innervation in patients with resistant hypertension","volume":"105","author":"Donazzan","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2025092004215557000_109.23.1734.10","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.03098"},{"key":"2025092004215557000_109.23.1734.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402670"},{"key":"2025092004215557000_109.23.1734.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu441"},{"key":"2025092004215557000_109.23.1734.13","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a Multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"The Lancet"},{"key":"2025092004215557000_109.23.1734.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022922"},{"key":"2025092004215557000_109.23.1734.15","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"The Lancet"},{"key":"2025092004215557000_109.23.1734.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq457"},{"key":"2025092004215557000_109.23.1734.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-009-0078-6"},{"key":"2025092004215557000_109.23.1734.18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)","volume":"139","author":"Fengler","year":"2019","journal-title":"Circulation"},{"key":"2025092004215557000_109.23.1734.19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05283"},{"key":"2025092004215557000_109.23.1734.20","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000977"},{"key":"2025092004215557000_109.23.1734.21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0000000000001584","article-title":"Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV","volume":"36","author":"Schmieder","year":"2018","journal-title":"J Hypertens"},{"key":"2025092004215557000_109.23.1734.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.10.061"},{"key":"2025092004215557000_109.23.1734.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32281-X"},{"key":"2025092004215557000_109.23.1734.24","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, International, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2025092004215557000_109.23.1734.25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"2025092004215557000_109.23.1734.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00788-1"},{"key":"2025092004215557000_109.23.1734.27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","article-title":"Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens Res"},{"key":"2025092004215557000_109.23.1734.28","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/eurheartj\/ehaa495","article-title":"Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis","volume":"41","author":"Lauder","year":"2020","journal-title":"Eur Heart J"},{"key":"2025092004215557000_109.23.1734.29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.121.057687","article-title":"Clinical trial design principles and outcomes definitions for device-based therapies for hypertension: a consensus document from the hypertension academic research consortium","volume":"145","author":"Kandzari","year":"2022","journal-title":"Circulation"},{"key":"2025092004215557000_109.23.1734.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.059"},{"key":"2025092004215557000_109.23.1734.31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","article-title":"Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension","volume":"80","author":"Sesa-Ashton","year":"2023","journal-title":"Hypertension"},{"key":"2025092004215557000_109.23.1734.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.10.048"},{"key":"2025092004215557000_109.23.1734.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.014"},{"key":"2025092004215557000_109.23.1734.34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007131","article-title":"Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension","volume":"6","author":"Doumas","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025092004215557000_109.23.1734.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202359","article-title":"Time spent at blood pressure target and the risk of death and cardiovascular diseases","volume":"13","author":"Chung","year":"2018","journal-title":"PLoS One"},{"key":"2025092004215557000_109.23.1734.36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jacc.2022.08.802","article-title":"Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range","volume":"80","author":"Mahfoud","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092004215557000_109.23.1734.37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcin.2022.10.058","article-title":"6- and 12-month follow-up from a randomized clinical trial of ultrasound vs radiofrequency renal denervation (RADIOSOUND-HTN)","volume":"16","author":"Fengler","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092004215557000_109.23.1734.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.089"},{"key":"2025092004215557000_109.23.1734.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.008"},{"key":"2025092004215557000_109.23.1734.40","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.117.09086","article-title":"Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up","volume":"69","author":"de Leeuw","year":"2017","journal-title":"Hypertension"},{"key":"2025092004215557000_109.23.1734.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2012.04.004"},{"key":"2025092004215557000_109.23.1734.42","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/CIRCRESAHA.118.313221","article-title":"Device-based neuromodulation for resistant hypertension therapy","volume":"124","author":"Lohmeier","year":"2019","journal-title":"Circ Res"},{"key":"2025092004215557000_109.23.1734.43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00392-019-01536-5","article-title":"Long-term effects of Baroreflex activation therapy: 2-year follow-up data of the BAT Neo system","volume":"109","author":"Wallbach","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2025092004215557000_109.23.1734.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32337-1"},{"key":"2025092004215557000_109.23.1734.45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcin.2021.12.015","article-title":"Treatment of resistant hypertension with endovascular baroreflex amplification: 3-year results from the CALM-FIM study","volume":"15","author":"van Kleef","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2025092004215557000_109.23.1734.46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006974","article-title":"Pacemaker-mediated programmable hypertension control therapy","volume":"6","author":"Neuzil","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025092004215557000_109.23.1734.47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad054"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:03Z","timestamp":1758367323000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":47,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,11,10]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/heartjnl-2022-321499"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321499","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}